NICOX SA (ALCOX.PA) Stock Price, Forecast & Analysis
Europe - EPA:ALCOX - FR0013018124 - Common Stock
ALCOX.PA Key Statistics, Chart & Performance
The current stock price of ALCOX.PA is 0.335 EUR. In the past month the price decreased by -5.37%. In the past year, price increased by 47.58%.
ALCOX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 71.56 | 47.32B | ||
| 1AE.DE | ARGENX SE | 72.42 | 47.89B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.31B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.07B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.18B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| 5CV.DE | CUREVAC NV | 5.3 | 1.04B | ||
| NANO.PA | NANOBIOTIX | N/A | 884.75M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 487.90M | ||
| FYB.DE | FORMYCON AG | N/A | 380.35M | ||
| VLA.PA | VALNEVA SE | N/A | 341.61M |
Related stock screener links
About ALCOX.PA
Company Profile
Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 5 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Info
NICOX SA
Sundesk Sophia Antipolis, Batiment C, Emerald Square, rue Evariste Galois
BIOT PACA FR
Employees: 5
Phone: 33497245300
NICOX SA / ALCOX.PA FAQ
What does NICOX SA do?
Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 5 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Can you provide the latest stock price for NICOX SA?
The current stock price of ALCOX.PA is 0.335 EUR. The price increased by 1.52% in the last trading session.
Does NICOX SA pay dividends?
ALCOX.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALCOX stock?
ALCOX.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ALCOX.PA stock?
9 analysts have analysed ALCOX.PA and the average price target is 1.53 EUR. This implies a price increase of 356.72% is expected in the next year compared to the current price of 0.335.
Can you provide the sector and industry classification for NICOX SA?
NICOX SA (ALCOX.PA) operates in the Health Care sector and the Biotechnology industry.
ALCOX.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALCOX.PA. When comparing the yearly performance of all stocks, ALCOX.PA turns out to be only a medium performer in the overall market: it outperformed 59.39% of all stocks.
ALCOX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALCOX.PA. ALCOX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALCOX.PA Financial Highlights
Over the last trailing twelve months ALCOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 23.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.83% | ||
| ROE | -653.37% | ||
| Debt/Equity | 4.4 |
ALCOX.PA Forecast & Estimates
9 analysts have analysed ALCOX.PA and the average price target is 1.53 EUR. This implies a price increase of 356.72% is expected in the next year compared to the current price of 0.335.
For the next year, analysts expect an EPS growth of 96% and a revenue growth 230% for ALCOX.PA